AA Financial Advisors LLC Buys 53 Shares of Stryker Co. (NYSE:SYK)

AA Financial Advisors LLC increased its stake in shares of Stryker Co. (NYSE:SYK) by 1.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 3,501 shares of the medical technology company’s stock after acquiring an additional 53 shares during the quarter. AA Financial Advisors LLC’s holdings in Stryker were worth $1,265,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of SYK. Park Avenue Securities LLC increased its stake in shares of Stryker by 8.7% during the first quarter. Park Avenue Securities LLC now owns 8,909 shares of the medical technology company’s stock worth $3,188,000 after purchasing an additional 715 shares during the period. Salem Investment Counselors Inc. grew its holdings in Stryker by 119.4% in the 1st quarter. Salem Investment Counselors Inc. now owns 4,747 shares of the medical technology company’s stock valued at $1,703,000 after buying an additional 2,583 shares in the last quarter. Cooper Financial Group increased its position in Stryker by 10.2% during the 1st quarter. Cooper Financial Group now owns 905 shares of the medical technology company’s stock worth $324,000 after buying an additional 84 shares during the period. Ballentine Partners LLC lifted its holdings in shares of Stryker by 2.6% during the first quarter. Ballentine Partners LLC now owns 7,039 shares of the medical technology company’s stock worth $2,519,000 after buying an additional 181 shares in the last quarter. Finally, Northwest Investment Counselors LLC bought a new stake in shares of Stryker in the first quarter valued at about $143,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of Stryker stock opened at $369.56 on Friday. The company’s 50 day moving average price is $355.79 and its two-hundred day moving average price is $343.26. The firm has a market capitalization of $140.83 billion, a P/E ratio of 41.20, a P/E/G ratio of 2.85 and a beta of 0.91. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.68 and a quick ratio of 0.95. Stryker Co. has a fifty-two week low of $255.22 and a fifty-two week high of $374.63.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.79 by $0.02. The business had revenue of $5.42 billion for the quarter, compared to analyst estimates of $5.40 billion. Stryker had a return on equity of 22.89% and a net margin of 16.12%. Stryker’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.54 EPS. On average, equities analysts forecast that Stryker Co. will post 12 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be given a dividend of $0.80 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.20 annualized dividend and a yield of 0.87%. Stryker’s dividend payout ratio is presently 35.67%.

Insiders Place Their Bets

In other news, VP M Kathryn Fink sold 2,121 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $370.00, for a total transaction of $784,770.00. Following the completion of the transaction, the vice president now owns 10,042 shares of the company’s stock, valued at approximately $3,715,540. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Viju Menon sold 600 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the transaction, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,715,540. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 220,068 shares of company stock valued at $71,811,372 in the last ninety days. 5.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

SYK has been the subject of several analyst reports. Barclays lifted their price objective on shares of Stryker from $374.00 to $402.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. Stifel Nicolaus dropped their price target on shares of Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a research report on Tuesday, October 1st. Truist Financial lifted their price objective on Stryker from $345.00 to $370.00 and gave the company a “hold” rating in a report on Monday, October 14th. Finally, Morgan Stanley increased their target price on Stryker from $345.00 to $350.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Four investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $381.16.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.